■螺旋藻(螺旋藻)是一种被证明具有抗炎作用的蓝细菌,抗病毒,和抗氧化作用。然而,目前尚不清楚大剂量螺旋藻补充剂对COVID-19住院成人的影响.本研究旨在评估大剂量螺旋藻治疗SARS-CoV-2感染的有效性和安全性。
■我们进行了随机,控制,开放标签试验,涉及189名COVID-19患者,以1:1的比例随机分配到接受15.2g螺旋藻补充剂加标准治疗的实验组(44名非重症监护病房(非ICU)和47名ICU),或单独接受标准治疗的对照组(46非ICU和52ICU)。该研究进行了六天。在第1、3、5和7天监测免疫介质。这项研究的主要结果是7天内的死亡率或出院,而总体出院或死亡率被认为是次要结局.
■在七天内,螺旋藻组没有死亡,对照组死亡15例(15.3%)。此外,七天之内,与对照组(39.1%)相比,非ICU中螺旋藻组(97.7%)的出院患者数量更多(HR,6.52;95%CI,3.50至12.17)。对照组的总死亡率更高(8.7%非ICU,28.8%ICU)与螺旋藻组(非ICUHR,0.13;95%CI,0.02至0.97;ICU,HR,0.16;95%CI,0.05至0.48)。在非重症监护病房,接受螺旋藻治疗的患者IL-6,TNF-α水平显着降低,IL-10和IP-10随介入时光的增长而增长。此外,在ICU,接受螺旋藻治疗的患者MIP-1α和IL-6水平显著降低.随着干预时间的增加,ICU和非ICU亚组干预组的IFN-γ水平均显着升高。在试验期间没有观察到与螺旋藻补充剂相关的副作用。
大剂量螺旋藻补充剂加上COVID-19的标准治疗可能会改善COVID-19住院患者的康复并显着降低死亡率。
■https://irct。ir/trial/54375,伊朗临床试验登记号(IRCT20210216050373N1)。
UNASSIGNED: Spirulina (arthrospira platensis) is a cyanobacterium proven to have anti-inflammatory, antiviral, and antioxidant effects. However, the effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19 is currently unclear. This study aimed to evaluate the efficacy and safety of high-dose Spirulina platensis for SARS-CoV-2 infection.
UNASSIGNED: We conducted a randomized, controlled, open-label trial involving 189 patients with COVID-19 who were randomly assigned in a 1:1 ratio to an experimental group that received 15.2g of Spirulina supplement plus standard treatment (44 non-intensive care unit (non-ICU) and 47 ICU), or to a control group that received standard treatment alone (46 non-ICU and 52 ICU). The study was conducted over six days. Immune mediators were monitored on days 1, 3, 5, and 7. The primary outcome of this study was mortality or hospital discharge within seven days, while the overall discharge or mortality was considered the secondary outcome.
UNASSIGNED: Within seven days, there were no deaths in the Spirulina group, while 15 deaths (15.3%) occurred in the control group. Moreover, within seven days, there was a greater number of patients discharged in the Spirulina group (97.7%) in non-ICU compared to the control group (39.1%) (HR, 6.52; 95% CI, 3.50 to 12.17). Overall mortality was higher in the control group (8.7% non-ICU, 28.8% ICU) compared to the Spirulina group (non-ICU HR, 0.13; 95% CI, 0.02 to 0.97; ICU, HR, 0.16; 95% CI, 0.05 to 0.48). In non-ICU, patients who received Spirulina showed a significant reduction in the levels of IL-6, TNF-α, IL-10, and IP-10 as intervention time increased. Furthermore, in ICU, patients who received Spirulina showed a significant decrease in the levels of MIP-1α and IL-6. IFN-γ levels were significantly higher in the intervention group in both ICU and non-ICU subgroups as intervention time increased. No side effects related to Spirulina supplements were observed during the trial.
UNASSIGNED: High-dose Spirulina supplements coupled with the standard treatment of COVID-19 may improve recovery and remarkably reduce mortality in hospitalized patients with COVID-19.
UNASSIGNED: https://irct.ir/trial/54375, Iranian Registry of Clinical Trials number (IRCT20210216050373N1).